EUVIMEDEUVIMED entdecken
Multizentrische Studie

Grandchildren of GRNDaD : Shifts in disease‐modifying therapy at the adolescent transition in sickle cell disease

Matthew Chang iD, Daniel Semakula, Jane A Little, Julie Kanter iD, Deepa G Manwani iD, Amma Owusu-Ansah, Alice J Cohen, Robert M Cronin, Payal C Desai, John J Strouse iD, Lisa M Shook iD, Farzana Sayani und 13 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20263 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Matthew Chang und 24 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Hydroxyurea, Registries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: HRSA HHS, Health Resources and Services Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Characterizing the modern person living with sickle cell disease (SCD) in the United States has been limited without a well‐curated longitudinal registry. To address this, the Globin Research Network for Data and Discovery (GRNDaD) registry strives to collect clinical outcomes and quality of life metrics from Institutional Review Board‐approved centres across the United States. Here, we examined the use of different disease‐modifying therapies in (actively consented) adults and children with HgbSS and HgbS‐β0 thalassaemia (SCA) from 38 sites. Of the 3169 active patients in GRNDaD, about 65% of subjects were on hydroxyurea (hydroxycarbamide; HU), and 2130 had SCA. As predicted, the absolute neutrophil counts were lower and mean corpuscular volumes were higher for patients on HU. However, there was a lower proportion of patients on HU in older age groups. In contrast, chronic RBC transfusion utilization was nearly twice as high in the 18‐ to 29‐year‐old age group than in the 11‐ to 17‐year‐old age group. For novel therapeutics, we examined use prior to voxelotor's removal from the market and prior to publication of the negative phase III trial of crizanlizumab. Voxelotor utilization in this cohort was three times that reported by claims data while crizanlizumab usage was nearly double, suggesting high‐quality comprehensive sickle cell care could increase utilization of novel therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellHydroxyureaRegistriesHumansAdolescentChildMaleFemaleAdultYoung AdultAntisickling AgentsUnited StatesChild, PreschoolQuality of Life

Stichwörter der Autor:innen

red cellssickle cell anaemiasickle cell disease

Substanzen

HydroxyureaAntisickling Agents

Autor:innen und Institutionen

  • Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • University of North Carolina, Chapel Hill, North Carolina, USA.
  • University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York, USA.
  • UH Rainbow Babies & Children's Hospital, Cleveland, Ohio, USA.
  • Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

ORCID-Profile: Matthew Chang, Julie Kanter, Deepa G Manwani, John J Strouse, Lisa M Shook, Alan R Anderson, Seethal A Jacob, Ofelia A Alvarez

Förderung

  • HRSA HHS
  • Health Resources and Services Administration

Zitieren

APA

Chang, M., Semakula, D., Little, J. A., Kanter, J., Manwani, D. G., Owusu-Ansah, A., Cohen, A. J., Cronin, R. M., Desai, P. C., Strouse, J. J., Shook, L. M., Sayani, F., LeBlanc, D., Treadwell, M. J., Betensky, M., Guarino, S. H., Mandernach, M. W., Anderson, A. R., Jacob, S. A., …, & Lanzkron, S. M. (2025). Grandchildren of GRNDaD : Shifts in disease‐modifying therapy at the adolescent transition in sickle cell disease. British Journal of Haematology. https://doi.org/10.1111/bjh.20263

Vancouver

Chang M, Semakula D, Little JA, Kanter J, Manwani DG, Owusu-Ansah A, et al. Grandchildren of GRNDaD : Shifts in disease‐modifying therapy at the adolescent transition in sickle cell disease. British Journal of Haematology. 2025. doi:10.1111/bjh.20263

BibTeX
@article{Chang2025,
  author = {Chang, Matthew and Semakula, Daniel and Little, Jane A and Kanter, Julie and Manwani, Deepa G and Owusu-Ansah, Amma and Cohen, Alice J and Cronin, Robert M and Desai, Payal C and Strouse, John J and Shook, Lisa M and Sayani, Farzana and LeBlanc, Dana and Treadwell, Marsha J and Betensky, Marisol and Guarino, Stephanie H and Mandernach, Molly W and Anderson, Alan R and Jacob, Seethal A and Saccente, Suzanne and Raj, Ashok B and Alvarez, Ofelia A and Saif Ur Rehman, Sana and Shah, Sanjay and Lanzkron, Sophie M},
  title = {Grandchildren of GRNDaD : Shifts in disease‐modifying therapy at the adolescent transition in sickle cell disease},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20263}
}
Kostenlos starten →